Welcome to our dedicated page for Exponent SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc EVP & CFO Richard L. Schlenker Jr. reported awards of stock options on February 20, 2026. He received 1,425 incentive stock options and 17,575 non-qualified stock options, each representing rights to buy Exponent shares. According to the footnotes, these options become exercisable in four equal annual installments.
Exponent Inc. President & CEO Catherine Corrigan exercised two non-qualified stock options, acquiring 3,226 and 2,380 shares of common stock at exercise prices of $25.4050 and $29.0500. She then sold a total of 3,920 shares of common stock, including 2,218 shares at $67.1646 and 1,702 shares at $67.1378, with the stock sale used to cover the option exercise price and taxes as noted in the footnotes.
Exponent Inc. insider Catherine Corrigan has filed a Form 144 notice to sell shares of EXPO common stock. The filing covers a planned sale of 3,920 common shares through Morgan Stanley Smith Barney LLC on or about 02/17/2026, with an aggregate market value of $261,816.80. The shares were acquired the same day by exercising stock options for cash.
The notice also reports prior Rule 10b5-1 plan sales over the past three months. These include 1,663 common shares sold on 01/15/2026 for gross proceeds of $120,593.78 and 3,225 common shares sold on 12/15/2025 for $240,171.23. Shares outstanding were 49,887,226 at the time referenced, providing context for the size of these trades.
Exponent Inc.'s Executive Vice President and Chief Financial Officer, Richard L. Schlenker Jr., reported an option exercise that increased his direct common stock holdings. On February 11, 2026, he exercised an Incentive Stock Option for 4,230 shares at an exercise price of $23.63 per share, converting the derivative position into common stock. Following this transaction, he directly owned 226,109 shares of Exponent common stock.
Exponent Inc.'s VP Global Offices & Innovation, John Pye, reported selling a total of 4,000 shares of common stock in open-market transactions on February 10, 2026. The sales occurred in two trades: 341 shares at $75.935 and 3,659 shares at $75.9781 per share.
Following these sales, Pye directly owns 25,204 shares of Exponent common stock. All reported holdings are listed as directly owned, with no indirect ownership disclosed in this filing.
A shareholder of EXPO has filed a notice of intent to sell 4,000 shares of common stock, with an aggregate market value of $303,897.70. The shares are listed as trading on NASDAQ, and the issuer reports 49,887,226 common shares outstanding at the time of the notice.
The filing details that the shares to be sold were acquired over several years through an employee stock purchase plan and restricted stock awards, with acquisition dates ranging from 2016 to 2025. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Exponent, Inc. filed a current report describing two key updates. The company issued a press release announcing its financial results for the fourth quarter ended January 2, 2026, which is attached as Exhibit 99.1. The detailed numbers are contained in that release.
Exponent also announced that its Board of Directors declared a quarterly cash dividend of $0.31 per share. This dividend will be paid on March 20, 2026 to common stockholders of record as of March 6, 2026, as disclosed in a separate press release attached as Exhibit 99.2.
Exponent, Inc. filed a current report describing two key updates. The company issued a press release announcing its financial results for the fourth quarter ended January 2, 2026, which is attached as Exhibit 99.1. The detailed numbers are contained in that release.
Exponent also announced that its Board of Directors declared a quarterly cash dividend of $0.31 per share. This dividend will be paid on March 20, 2026 to common stockholders of record as of March 6, 2026, as disclosed in a separate press release attached as Exhibit 99.2.
Exponent Inc. President & CEO Catherine Corrigan reported an option exercise and related stock sale. On 01/15/2026, she exercised a non-qualified stock option for 2,380 shares of common stock at an exercise price of $29.05 per share, increasing her directly held common stock to 94,386 shares.
On the same date, she sold 1,663 shares of Exponent common stock at an average price of $72.5158 per share in an open-market sale, leaving her with 92,723 shares of common stock directly owned after the sale. Following the option exercise, she also directly holds 16,658 non-qualified stock options, which the filing notes become exercisable in four equal annual installments and are scheduled to expire on 02/16/2027.
A person associated with EXPO has filed a Form 144 notice to sell 1,663 shares of common stock through Morgan Stanley Smith Barney LLC on or around 01/15/2026 on the NASDAQ. These shares were acquired the same day by exercising stock options and paid for in cash.
The notice also lists prior Rule 10b5-1 plan sales for Catherine Corrigan in the past three months, including 3,225 shares sold on 12/15/2025 for gross proceeds of $240,171.23, and additional sales of 3,225 shares and 1,675 shares on 11/17/2025 for gross proceeds of $226,411.13 and $118,487.32, respectively.
Conestoga Capital Advisors filed Amendment No. 3 to a Schedule 13G reporting its beneficial ownership of 2,526,244 shares of Exponent Inc common stock, representing 5.06% of the outstanding class as of 12/31/2025. Conestoga has sole power to vote and dispose of 2,392,498 of these shares and no shared voting or dispositive power. The firm is classified as an investment adviser and certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Exponent Inc.